Zuzana Zachar

Chief Tech/Sci/R&D Officer at Cornerstone Pharmaceuticals, Inc.

Consumer Services

Commercial Services

Profile

Zuzana Zachar is currently working as a Research Director at Cornerstone Pharmaceuticals, Inc. She holds a doctorate degree from Stony Brook University and a graduate degree from the University of Illinois.

Zuzana Zachar active positions

Companies	Position	Start
Cornerstone Pharmaceuticals, Inc. Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.	Chief Tech/Sci/R&D Officer	16/04/2009

All active positions of Zuzana Zachar

Training of Zuzana Zachar

University of Illinois	Graduate Degree
Stony Brook University	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Zuzana Zachar's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Cornerstone Pharmaceuticals, Inc. Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.	Commercial Services